Beranda › Leukemia Limfositik Kronis
Uji klinis Leukemia Limfositik Kronis yang merekrut di AS
120 studi untuk Leukemia Limfositik Kronis merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Boston, MA31 studi
- Columbus, OH28 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA21 studi
- Rochester, MN19 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Cincinnati, OH14 studi
- Milwaukee, WI14 studi
- Chicago, IL14 studi
- Nashville, TN13 studi
- Jacksonville, FL11 studi
- Philadelphia, PA11 studi
- Atlanta, GA11 studi
- Pittsburgh, PA10 studi
- Portland, OR10 studi
- San Diego, CA10 studi
- Dallas, TX10 studi
- Kansas City, MO10 studi
- Salt Lake City, UT10 studi
- Charlotte, NC9 studi
- Miami, FL9 studi
- Winston-Salem, NC8 studi
- Tampa, FL8 studi
- Minneapolis, MN8 studi
- Denver, CO8 studi
- St. Louis, MO8 studi
- Des Moines, IA8 studi
- Los Angeles, CA8 studi
- Queens, NY8 studi
- Omaha, NE8 studi
- Clifton, NJ7 studi
- Fort Wayne, IN7 studi
- Billings, MT7 studi
- Cedar Rapids, IA7 studi
- Mountain View, CA7 studi
- Aurora, CO7 studi
- Cleveland, OH7 studi
Berdasarkan negara bagian
- Alabama7 studi
- Arizona15 studi
- Arkansas4 studi
- California33 studi
- Colorado16 studi
- Connecticut5 studi
- Delaware4 studi
- Distrik Columbia4 studi
- Florida34 studi
- Georgia16 studi
- Idaho4 studi
- Illinois17 studi
- Indiana12 studi
- Iowa10 studi
- Kansas6 studi
- Kentucky7 studi
- Louisiana6 studi
- Maine6 studi
- Maryland23 studi
- Massachusetts33 studi
- Michigan12 studi
- Minnesota29 studi
- Mississippi5 studi
- Missouri13 studi
- Montana7 studi
- Nebraska8 studi
- Nevada6 studi
- New Hampshire3 studi
- New Jersey13 studi
- New Mexico3 studi
- New York26 studi
- North Carolina34 studi
- Ohio43 studi
- Oklahoma4 studi
- Oregon16 studi
- Pennsylvania22 studi
- Rhode Island5 studi
- South Carolina5 studi
- South Dakota3 studi
- Tennessee17 studi
- Texas38 studi
- Utah10 studi
- Virginia11 studi
- Washington27 studi
- Wisconsin19 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT03516617A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07582432A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05645107Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT04269902A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06542250A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06697184Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Menerima pesertaStudi observasional
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT00923507A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07277231A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
Usia 75 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07685717A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06973187Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Menerima pesertaFase 2
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT03986034A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06136559A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05947851Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06784167A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07218341Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT01087333Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07221500Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07194980Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07061951Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04169737Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07225439Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.